Goldman Sachs
BMY.RT

Goldman Sachs’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Goldman Sachs’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,374,383
Closed -$3.02M – 6593
2020
Q4 		$3.02M Sell
4,374,383
-535,342
-11% -$1.14M ﹤0.01% 3413
2020
Q3 		$11M Sell
4,909,725
-305,597
-6% -$873K ﹤0.01% 2235
2020
Q2 		$18.7M Sell
5,215,322
-614,760
-11% -$2.22M 0.01% 1736
2020
Q1 		$22.2M Buy
5,830,082
+181,881
+3% +$599K 0.01% 1429
2019
Q4 		$17M Buy
+5,648,201
New +$14.7M ﹤0.01% 2003

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Goldman Sachs's BMY.RT Position: Q1 2021 in Review

Goldman Sachs sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 4,374,383 shares — an estimated $3.02M sold.

Goldman Sachs first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $22.2M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Goldman Sachs reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Goldman Sachs sold 4,374,383 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $3.02M.
  • Goldman Sachs first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Goldman Sachs's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $22.2M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Goldman Sachs's 13F filing for Q1 2021, filed 17 May 2021.